BLMH.c rallies 22% this week. Ahead of the company’s fiscal year-end results, Bloom Health Partners (CSE: BLMH) shares have begun to rally, gaining 22% so far this week.
BLMH is expected to beat its yearly earnings benchmarks, as the company has already recorded $24.9 million in revenue as of fiscal Q3. The company’s highest earning benchmark was set at $28 million, so unless the company records a record low quarter, things are looking very good.
The company is presently valued at only $6.67 million, representing a massive undervaluation in my opinion. Based on BLMH’s YTD EBITDA, which is a much more conservative metric, the company should theoretically be trading at a valuation of around $70 million based on its YTD earnings.
The company is expected to release its year-end results before the end of November.
BLMH.c is currently trading at $.14.
https://ceo.ca/@newsfile/bloom-health-partners-reports-profitable-fiscal-q3